Method for production of bioresorable microparticles, microparticles thus obtained and use thereof

Abstract

The present invention relates to a method for preparing nonlamellar bioresorbable microparticles to which protein substances are bonded, characterized in that it comprises the steps of: (i) preparing said microparticles from at least one bioresorbable polymer without stabilizer and without surfactant, and (ii) bonding said protein substances to the microparticles obtained in step (i) without surfactant. It further relates to the bioresorbable microparticles thus obtained and use thereof in diagnosis and therapy.

1 . A method for preparing nonlamellar bioresorbable microparticles to which protein substances are bonded, characterized in that it comprises the steps of: 
 (i) preparing said microparticles from at least one bioresorbable polymer without stabilizer and without surfactant, and    (ii) bonding said protein substances to the microparticles obtained in step (i) without surfactant.    
     
     
         2 . The method as claimed in  claim 1 , characterized in that the polymer used in step (i) is a poly(α-hydroxylated acid) or a mixture of poly(α-hydroxylated acids).  
     
     
         3 . The method as claimed in  claim 1 , characterized in that the bonding of the protein substances to the microparticles is carried out by adsorption.  
     
     
         4 . The method as claimed in  claim 1 , characterized in that the protein substance is an antigen of viral origin.  
     
     
         5 . The method as claimed in  claim 4 , characterized in that the antigen is an HIV virus antigen, preferably the p24 protein or a regulatory protein.  
     
     
         6 . The method as claimed in  claim 5 , characterized in that the HIV virus antigen is a regulatory protein chosen from the Tat, Rev and Nef proteins.  
     
     
         7 . The method as claimed in  claim 4 , characterized in that the antigen is an HCV virus antigen, preferably a nonstructural protein of the HCV virus.  
     
     
         8 . The method as claimed in  claim 7 , characterized in that the antigen is the NS3 protein, preferably the NS3 helicase protein.  
     
     
         9 . Bioresorbable nonlamellar microparticles to which protein substances are bonded, obtainable by the method as claimed in  claim 1 .  
     
     
         10 . A method of preparing a medicinal product comprising using bioresorbable microparticles as defined in  claim 9  for preparing said medicinal product.  
     
     
         11 . The method as claimed in  claim 10 , characterized in that the medicinal product is intended for the inhibition, prevention or treatment of an infection caused by a virus.  
     
     
         12 . A pharmaceutical composition, in particular a vaccine, characterized in that it contains at least one bioresorbable microparticle as defined in  claim 9  and, where appropriate, a pharmaceutically acceptable excipient.  
     
     
         13 . A method of treating pathologies associated with the protein substance bonded to a bioresorbable microparticle as defined in  claim 9 , obtainable 
 (i) preparing said microparticle from at least one bioresorbable polymer without stabilizer and without surfactant, and    (ii) bonding said protein substances to the microparticle obtained in step (i) without surfactant;    which comprises the administration, to a patient, of an effective dose of a pharmaceutical composition as defined in  claim 12 .    
     
     
         14 . Antibodies directed against the bioresorbable microparticles as defined in  claim 9 .  
     
     
         15 . A diagnostic composition consisting of the bioresorbable microparticles as defined in  claim 9  or of antibodies against said bioresorbable microparticles.  
     
     
         16 . A diagnostic method comprising using the diagnostic composition as defined in  claim 15 , for the in vitro diagnosis of a pathological state related to the protein substance bonded to the bioresorbable microparticle.  
     
     
         17 . The method as claimed in  claim 16 , characterized in that the pathological state is a viral infection.